Monell Scientists Locate Region of Brain Activated by GLP1 drugs That Can Reduce Food Intake Without Nausea

Because we found that GLP1 drugs can activate a neuron population in the brain to reduce food intake without nausea, the implication is that future obesity drugs could be developed to selectively promote satiety without the negative side effects.

WeightControl.com Interview with:

Amber L. Alhadeff, Ph.D.
Principal Investigator
Monell Chemical Senses Center &
Department of Neuroscience, University of Pennsylvania
Philadelphia, PA 19104

WeightControl.com:  What is the background for this study? 

Response: GLP1-based weight loss drugs have become extremely popular, but we don’t have a good understanding of how they work. Further, many people who take these drugs experience nausea and other gastrointestinal side effects – some more severe than others.

Because of this, we became interested in understanding whether the appetite loss and weight loss stem from the same or different neural circuits as those that mediate the nausea. 

Last Updated on July 30, 2024 by weightcontrol

Pages: Page 1, Page 2